Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

25.10
+2.6511.80%
Pre-market: 25.08-0.0200-0.08%06:35 EDT
Volume:3.83M
Turnover:93.65M
Market Cap:2.54B
PE:-5.43
High:25.13
Open:23.22
Low:23.00
Close:22.45
52wk High:35.25
52wk Low:13.53
Shares:101.16M
Float Shares:89.94M
Volume Ratio:1.31
T/O Rate:4.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6207
EPS(LYR):-4.5769
ROE:-41.94%
ROA:-21.02%
PB:2.43
PE(LYR):-5.48

Loading ...

Dec 30, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 30, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 09, 2024

Major Issues Report

Form 8-K - Current report
Dec 06, 2024

Major Issues Report

Form 8-K - Current report
Dec 04, 2024

Major Issues Report

Form 8-K - Current report
Nov 07, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 05, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2024

Major Issues Report

Form 8-K - Current report
Nov 05, 2024

Major Issues Report

Form 8-K - Current report
Nov 05, 2024

Major Issues Report

Form 8-K - Current report
Oct 17, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Oct 15, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 07, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 30, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2024

Major Issues Report

Form 8-K - Current report
Jul 15, 2024

Major Issues Report

Form 8-K - Current report
Jun 28, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2024

Major Issues Report

Form 8-K - Current report
May 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]